- Molecular NameEthopropazine
- SynonymAethopropropazin; Athapropazine; Athopropazin; Ethapropazine; Ethopromazine; Ethopropazine Hydrochloride; Etopropezina; Fempropazine; Fenpropazina; Isopthazine; Isotazin; Isothazine; Isothazine hydrochloride; Isothiazine; Phenopropazine; Phenoprozine; Prodierazine; Profenamina [INN-Spanish]; Profenamina [Italian]; Profenamine; Profenamine hydrochloride; Profenamine monohydrochloride; Profenaminum [INN-Latin]; Prophenamine; Prophenaminum
- Weight312.481
- Drugbank_IDDB00392
- ACS_NO1094-08-2
- Show 2D model
- LogP (experiment)4.77
- LogP (predicted, AB/LogP v2.0)5.14
- pka8.5
- LogD (pH=7, predicted)2.81
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.84
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors0
- No.of HBond Acceptors2
- No.of Rotatable Bonds5
- TPSA31.78
- StatusFDA approved
- AdministrationN/A
- PharmacologyPhenothiazine derivative with antimuscarinic, adrenergic-blocking, antihistaminic, local anaesthetic and ganglion-blocking properties. It is primarily used as an antidyskinetic to treat parkinsonism, including the alleviation of the extrapyramidal syndrome induced by drugs such as other phenothiazine compounds, but, like other compounds with antimuscarinic properties, is of no value against tardive dyskinesias.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability5.0
- Protein binding93.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half life1~2 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A